-
Join 37 other subscribers
Categories
Top Posts
Blogroll
Tag Archives: AstraZeneca
Pfizer gives up the chase.
Pfizer is saying today that it does not intend to extend a firm offer for AstraZeneca, bringing an end to its attempt to acquire the UK drug maker. AZ shareholders were split on the latest offer, and a stumble by AZ would … Continue reading
Pfizer raises its bid for AstraZeneca – one last time?
Over the weekend, Pfizer finally made an official offer for AstraZeneca, by raising its bid to $119B (15% higher than the last, unofficial, offer), and increasing the cash portion of the deal from 33% to 45%. AZ had a market cap of … Continue reading
Posted in Pharmaceutical Industry
Tagged acquisition, AstraZeneca, megamerger, Pfizer
Leave a comment
Pfizer is a shark that can’t stop feeding
So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, Consolidation, merger, Pfizer, Pharmaceutical industry
Leave a comment
Pfizer won’t take no for an answer
Amidst several indications that Pfizer will launch a hostile bid for AstraZeneca if necessary, this quote stands out: Asked whether hostile moves could hurt integration of the two companies, Chief Executive Ian Read said, “No, in my opinion, all it … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, hostile takeover, Ian Read, merger, Pfizer
Leave a comment
Pfizer’s real strategy is (mostly) tax-minimization
Many observers were initially left scratching their heads over Pfizer’s pursuit of AstraZeneca, a company that has had major pipeline troubles of its own. As more information has come out, Pfizer’s strategy is beginning to make sense. They aren’t pursuing an old-style mega … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, merger, Pfizer, Pharma, tax-avoidance
1 Comment
Undeterred, Pfizer continues its mega merger strategy
Pfizer continues to stalk AstraZeneca, even as other firms abandon mega mergers.
MechanizedIntelligence 